In 2025, only four of the top ten animal health companies made acquisitions, the joint lowest on record. M&A spend fell from $8.8bn to $1.7bn. Deal volume dropped, but diligence quality went up. Acquirers and licensees are more selective, more data-driven, and more focused on development-stage risk than at any point in the last decade. This session pulls back the curtain on what drives deal decisions, and what founders and development teams need to build in from day one.
- What a diligence-ready data package looks like
- What kills deals: the most common data gaps, red flags, and avoidable mistakes
- Licensing vs acquisition vs co-development: which structure fits which stage
- How acquirers are pricing development-stage assets as valuations shift from revenue to data
- What investors are underwriting and how to de-risk your development plan before the pitch
Speaker(s):
Time:
3:20pm-3:50pm
Agenda Track No.:
Track 8
Session Type:
General Session (Presentation)
Force Inline Description:
0